vs
Fastenal（FAST）与豪洛捷（HOLX）财务数据对比。点击上方公司名可切换其他公司
Fastenal的季度营收约是豪洛捷的1.9倍（$2.0B vs $1.0B），豪洛捷净利率更高（17.1% vs 14.5%，领先2.6%），Fastenal同比增速更快（3.5% vs 2.5%），Fastenal自由现金流更多（$308.2M vs $215.2M），过去两年Fastenal的营收复合增速更高（2.9% vs 1.5%）
Fastenal是1967年成立的美国上市企业，总部位于明尼苏达州威诺纳，是北美最大的紧固件分销商，同时也是工业和建筑用品的主流供应商，可提供货柜备货、智能售货柜、库存管理、物流配送等一站式供应链解决方案。
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
FAST vs HOLX — 直观对比
营收规模更大
FAST
是对方的1.9倍
$1.0B
营收增速更快
FAST
高出0.9%
2.5%
净利率更高
HOLX
高出2.6%
14.5%
自由现金流更多
FAST
多$93.0M
$215.2M
两年增速更快
FAST
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.0B | $1.0B |
| 净利润 | $293.9M | $179.1M |
| 毛利率 | 44.3% | 56.0% |
| 营业利润率 | 18.9% | 22.6% |
| 净利率 | 14.5% | 17.1% |
| 营收同比 | 3.5% | 2.5% |
| 净利润同比 | -1.6% | -10.9% |
| 每股收益（稀释后） | $-0.01 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FASTHOLX
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $1.0B | ||
| Q3 25 | $2.1B | $1.0B | ||
| Q2 25 | $2.1B | $1.0B | ||
| Q1 25 | $2.0B | $1.0B | ||
| Q4 24 | $1.8B | $1.0B | ||
| Q3 24 | $1.9B | $988.0M | ||
| Q2 24 | $1.9B | $1.0B |
净利润FASTHOLX
| Q1 26 | $293.9M | — | ||
| Q4 25 | $293.9M | $179.1M | ||
| Q3 25 | $335.5M | $187.2M | ||
| Q2 25 | $330.3M | $194.9M | ||
| Q1 25 | $298.7M | $-17.4M | ||
| Q4 24 | $262.1M | $201.0M | ||
| Q3 24 | $298.1M | $178.6M | ||
| Q2 24 | $292.7M | $194.5M |
毛利率FASTHOLX
| Q1 26 | 44.3% | — | ||
| Q4 25 | 44.3% | 56.0% | ||
| Q3 25 | 45.3% | 55.6% | ||
| Q2 25 | 45.3% | 56.3% | ||
| Q1 25 | 45.1% | 37.5% | ||
| Q4 24 | 44.8% | 56.8% | ||
| Q3 24 | 44.9% | 56.4% | ||
| Q2 24 | 45.1% | 55.4% |
营业利润率FASTHOLX
| Q1 26 | 18.9% | — | ||
| Q4 25 | 18.9% | 22.6% | ||
| Q3 25 | 20.7% | 22.6% | ||
| Q2 25 | 21.0% | 24.9% | ||
| Q1 25 | 20.1% | -0.7% | ||
| Q4 24 | 18.9% | 22.5% | ||
| Q3 24 | 20.3% | 23.3% | ||
| Q2 24 | 20.2% | 24.1% |
净利率FASTHOLX
| Q1 26 | 14.5% | — | ||
| Q4 25 | 14.5% | 17.1% | ||
| Q3 25 | 15.7% | 17.8% | ||
| Q2 25 | 15.9% | 19.0% | ||
| Q1 25 | 15.2% | -1.7% | ||
| Q4 24 | 14.4% | 19.7% | ||
| Q3 24 | 15.6% | 18.1% | ||
| Q2 24 | 15.3% | 19.2% |
每股收益（稀释后）FASTHOLX
| Q1 26 | $-0.01 | — | ||
| Q4 25 | $-0.01 | $0.79 | ||
| Q3 25 | $0.29 | $0.84 | ||
| Q2 25 | $0.29 | $0.86 | ||
| Q1 25 | $0.52 | $-0.08 | ||
| Q4 24 | $0.45 | $0.87 | ||
| Q3 24 | $0.52 | $0.75 | ||
| Q2 24 | $0.51 | $0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $276.8M | $2.4B |
| 总债务越低越好 | $125.0M | $2.5B |
| 股东权益账面价值 | $3.9B | $5.2B |
| 总资产 | $5.1B | $9.2B |
| 负债/权益比越低杠杆越低 | 0.03× | 0.48× |
8季度趋势，按日历期对齐
现金及短期投资FASTHOLX
| Q1 26 | $276.8M | — | ||
| Q4 25 | $276.8M | $2.4B | ||
| Q3 25 | $288.1M | $2.2B | ||
| Q2 25 | $237.8M | $1.9B | ||
| Q1 25 | $231.8M | $1.6B | ||
| Q4 24 | $255.8M | $2.0B | ||
| Q3 24 | $292.2M | $2.3B | ||
| Q2 24 | $255.5M | $2.4B |
总债务FASTHOLX
| Q1 26 | $125.0M | — | ||
| Q4 25 | $125.0M | $2.5B | ||
| Q3 25 | $195.0M | $2.5B | ||
| Q2 25 | $230.0M | $2.5B | ||
| Q1 25 | $200.0M | $2.5B | ||
| Q4 24 | $200.0M | $2.5B | ||
| Q3 24 | $240.0M | $2.5B | ||
| Q2 24 | $235.0M | $2.5B |
股东权益FASTHOLX
| Q1 26 | $3.9B | — | ||
| Q4 25 | $3.9B | $5.2B | ||
| Q3 25 | $3.9B | $5.0B | ||
| Q2 25 | $3.8B | $4.8B | ||
| Q1 25 | $3.7B | $4.6B | ||
| Q4 24 | $3.6B | $4.8B | ||
| Q3 24 | $3.6B | $5.1B | ||
| Q2 24 | $3.5B | $5.0B |
总资产FASTHOLX
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.1B | $9.2B | ||
| Q3 25 | $5.1B | $9.0B | ||
| Q2 25 | $5.0B | $8.8B | ||
| Q1 25 | $4.9B | $8.5B | ||
| Q4 24 | $4.7B | $8.7B | ||
| Q3 24 | $4.7B | $9.2B | ||
| Q2 24 | $4.6B | $8.9B |
负债/权益比FASTHOLX
| Q1 26 | 0.03× | — | ||
| Q4 25 | 0.03× | 0.48× | ||
| Q3 25 | 0.05× | 0.50× | ||
| Q2 25 | 0.06× | 0.52× | ||
| Q1 25 | 0.05× | 0.55× | ||
| Q4 24 | 0.06× | 0.53× | ||
| Q3 24 | 0.07× | 0.49× | ||
| Q2 24 | 0.07× | 0.51× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $368.2M | $229.9M |
| 自由现金流经营现金流 - 资本支出 | $308.2M | $215.2M |
| 自由现金流率自由现金流/营收 | 15.2% | 20.5% |
| 资本支出强度资本支出/营收 | 3.0% | 1.4% |
| 现金转化率经营现金流/净利润 | 1.25× | 1.28× |
| 过去12个月自由现金流最近4个季度 | $1.2B | $1.0B |
8季度趋势，按日历期对齐
经营现金流FASTHOLX
| Q1 26 | $368.2M | — | ||
| Q4 25 | $368.2M | $229.9M | ||
| Q3 25 | $386.9M | $355.1M | ||
| Q2 25 | $278.6M | $343.3M | ||
| Q1 25 | $262.2M | $169.4M | ||
| Q4 24 | $282.8M | $189.3M | ||
| Q3 24 | $296.9M | $367.0M | ||
| Q2 24 | $258.0M | $405.8M |
自由现金流FASTHOLX
| Q1 26 | $308.2M | — | ||
| Q4 25 | $308.2M | $215.2M | ||
| Q3 25 | $326.6M | $341.4M | ||
| Q2 25 | $209.3M | $330.5M | ||
| Q1 25 | $206.5M | $153.9M | ||
| Q4 24 | $222.6M | $172.5M | ||
| Q3 24 | $237.5M | $350.6M | ||
| Q2 24 | $201.9M | $385.3M |
自由现金流率FASTHOLX
| Q1 26 | 15.2% | — | ||
| Q4 25 | 15.2% | 20.5% | ||
| Q3 25 | 15.3% | 32.5% | ||
| Q2 25 | 10.1% | 32.3% | ||
| Q1 25 | 10.5% | 15.3% | ||
| Q4 24 | 12.2% | 16.9% | ||
| Q3 24 | 12.4% | 35.5% | ||
| Q2 24 | 10.5% | 38.1% |
资本支出强度FASTHOLX
| Q1 26 | 3.0% | — | ||
| Q4 25 | 3.0% | 1.4% | ||
| Q3 25 | 2.8% | 1.3% | ||
| Q2 25 | 3.3% | 1.3% | ||
| Q1 25 | 2.8% | 1.5% | ||
| Q4 24 | 3.3% | 1.6% | ||
| Q3 24 | 3.1% | 1.7% | ||
| Q2 24 | 2.9% | 2.0% |
现金转化率FASTHOLX
| Q1 26 | 1.25× | — | ||
| Q4 25 | 1.25× | 1.28× | ||
| Q3 25 | 1.15× | 1.90× | ||
| Q2 25 | 0.84× | 1.76× | ||
| Q1 25 | 0.88× | — | ||
| Q4 24 | 1.08× | 0.94× | ||
| Q3 24 | 1.00× | 2.05× | ||
| Q2 24 | 0.88× | 2.09× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FAST
| Reportable Segment Aggregation Before Other Operating Segment | $1.8B | 90% |
| Other | $211.2M | 10% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
